The Oncology Institute, Inc.

The Oncology Institute, Inc.

NNASDAQ:TOI
6.35
USD
+0.14
(+2.17%)
-0.36EPS
545.55MMarket Cap

Total Valuation

USD

As of June 30, 2026, The Oncology Institute, Inc. carries a market capitalization of 545.55M, placing it among publicly traded companies globally. Its enterprise value stands at 608.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap545.55M
Enterprise Value608.93M

Important Dates

The Oncology Institute, Inc.'s next confirmed earnings release is scheduled for August 6, 2026.

Earnings Date8/6/2026

Share Statistics

As of June 30, 2026, The Oncology Institute, Inc. has 100.47M shares outstanding.

Shares Outstanding100.47M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 0.93, and the price-to-book ratio stands at -21.90.

PS Ratio0.93
PB Ratio-21.90
P/TBV Ratio-13.07
P/FCF Ratio-166.80
P/OCF Ratio1,671.07

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 1.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 608.93M versus a market cap of 545.55M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.04

Financial Position

As of June 30, 2026, The Oncology Institute, Inc. maintains a current ratio of 1.36, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -419.35, indicating conservative leverage, while an interest coverage ratio of -2.53 demonstrates limited ability to service its debt obligations.

Current Ratio1.36
Quick Ratio1.14
Debt / Equity-419.35
Debt / EBITDA-5.42
Interest Coverage-2.53

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -21.47, reflecting losses generated across the asset base. The company generates approximately 854,794.76 in revenue per employee across its workforce of 687.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 27.66 indicates how many times The Oncology Institute, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-21.47
Revenue Per Employee854,794.76
Employee Count687.00
Inventory Turnover27.66

Stock Price Statistics

USD

As of the close on October 2, 2026, The Oncology Institute, Inc.'s stock has gained approximately 84.59% over the past 52 weeks. The 50-day moving average sits at 6.11, while the 200-day moving average is 4.41.

52-Week Price Change84.59%
50-Day Moving Average6.11
200-Day Moving Average4.41

Income Statement

USD

Over the twelve months ended June 30, 2026, The Oncology Institute, Inc. generated 587.24M in revenue and converted that into -36.29M in net income, yielding earnings per share of -0.36. EBITDA reached -19.28M, while operating income came in at -26.09M.

Revenue587.24M
Gross Profit92.17M
Operating Income-26.09M
Pretax Income-36.29M
Net Income-36.29M
EBITDA-19.28M
EBIT-26.09M
Earnings Per Share (EPS)-0.36

Balance Sheet

USD

As of June 30, 2026, The Oncology Institute, Inc. holds 41.09M in cash and equivalents against 104.48M in total debt, resulting in a net debt position of 38.77M. Total book value stands at -24.91M, with working capital of 34.05M providing operational flexibility.

Cash & Cash Equivalents41.09M
Total Debt104.48M
Net Debt38.77M
Equity (Book Value)-24.91M
Book Value Per Share-0.25
Working Capital34.05M

Cash Flow

USD

The Oncology Institute, Inc. produced 328,000.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.61M in capital expenditures, free cash flow totaled -3.29M - equivalent to -0.03 per share.

Operating Cash Flow328,000.00
Capital Expenditures-3.61M
Free Cash Flow-3.29M
FCF Per Share-0.03

Margins

Over the twelve months ended June 30, 2026, The Oncology Institute, Inc. posted a gross margin of 15.69, reflecting its pricing power and cost economics. The operating margin of -4.44 and net profit margin of -6.18 provide insight into operational efficiency.

Gross Margin15.69
Operating Margin-4.44
Pretax Margin-6.18
Profit Margin-6.18
EBITDA Margin-3.28

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.58, meaning The Oncology Institute, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-2.58
FCF Yield-0.60

Scores

As of June 30, 2026, The Oncology Institute, Inc. has an Altman Z-Score of 2.51, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.51